One user shared their success story, reporting a 47-lb weight loss over four months, crediting the app's precise medication tracking
Despite how common GLP-1 use has become, there has been relatively little dermatology-focused research on their cutaneous side effects, with most of the existing literature limited to individual case reports. For the cross-sectional analysis, Fat and colleagues compared cutaneous adverse events reported in the FDA Adverse Event Reporting System (FAERS) for the GLP-1 receptor agonists semaglutide (Ozempic/ Wegovy, Novo Nordisk), liraglutide, exenatide and dulaglutide (Trulicity, Eli Lilly) with cutaneous adverse event reports for the dipeptidyl peptidase-4 (DPP-IV) inhibitors sitagliptin, saxagliptin, linagliptin and alogliptin
Annals of the New York Academy of Sciences, 2004.
GLP -1 are great drugs for diabetic patients and certain metabolic diseases but they were being promoted as quick weight loss drugs for brides and grooms and this is unethical